Presented by the University of Texas Southwestern Medical Center.
A Closer Look at Pharmacologic Options
Osteoarthritis (OA) is the most common form of arthritis, and nearly 27 million US adults exhibit clinically evident OA. While nonpharmacologic interventions for OA, such as exercise, weight reduction, and patient education are advocated as primary therapy to manage OA, these goals are often difficult to achieve, and many patients with OA rely on pharmacologic therapies to control OA pain. Oral analgesics, including acetaminophen and nonsteroidal anti-inflammatory drugs, are commonly prescribed to manage OA, but can be associated with important risks, especially in a patient population with a high likelihood of underlying comorbidities. As such, pharmacologic options for OA often require consideration of cardiac, gastric, renal, and hematologic issues to maintain patient safety. With a changing understanding of OA pathophysiology, including the role of inflammation, obesity, and nociceptive pain, management strategies have substantially evolved. This activity will concentrate on the pharmacologic management of OA with oral agents and the relative efficacy and potential safety risks associated with these systemic therapies.
To provide primary care physicians with up-to-date information on the pharmacologic management of OA with oral agents and the relative efficacy and potential safety risks associated with these systemic therapies.
This activity has been designed to meet the educational needs of primary care physicians who manage and treat patients with OA. No prerequisites required.
At the conclusion of this educational activity, the participants should be able to:
- Discuss optimal approaches to the comanagement of cardiovascular disease in patients with OA. [MK, PC]
- Recognize differences in the efficacy and tolerability among classes of gastroprotective agents used to mitigate GI adverse events in OA patients managed with an NSAID. [MK]
- Analyze the risks and benefits of nonnarcotic and narcotic analgesics used to manage pain for patients with OA. [MK]
- Evaluate current and emerging ideas about OA pathophysiology and how to translate them into clinical management of OA for improved patient outcomes. [MK, PC]
Accreditation Council for Graduate Medical Education General Competency Assignments
PC Patient Care
MK Medical Knowledge
IC Interpersonal & Communication Skills
SB Systems-Based Practice
PB Practice-Based Learning & Improvement
Source: Accreditation Council for Graduate Medical Education. Common Program Requirements: General Competencies. Available at: http://www.acgme.org/outcome/comp/GeneralCompetenciesStandards21307.pdf. Published: September 28, 1999. Accessed December 4, 2009.
The University of Texas Southwestern Medical Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The University of Texas Southwestern Medical Center designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credits
™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
The estimated time to complete this activity: 1 hour 30 minutes.
Release date: November 30, 2010. Expiration date: November 30, 2012.
The following interactive case activity consists of 3 sections: a pre-test, an interactive activity with cases and decision points, and a CME post-test with an evaluation. All 3 sections must be completed to receive CME credit. A certificate of participation will be available online immediately following successful completion of the module.
It is UT Southwestern’s policy that participants in CME activities should be made aware of any affiliation or financial interest that may affect the speaker’s presentation(s). Each speaker has completed and signed a conflict of interest statement. All individuals in a position to control content have disclosed the following:
John J. Cush, MD (Chair)
Clinical Professor of Internal Medicine
The University of Texas Southwestern Medical School
Professor of Medicine and Rheumatology
Baylor University Medical Center
Dr Cush reports serving as a clinical investigator for Abbott Laboratories, Celgene Corporation, Centocor, CORRONA, Genentech/Roche, Pfizer Inc, and UCB; and serving as an advisor and consultant for Abbott Laboratories, Amgen, Inc, Bristol-Myers Squibb, Centocor, Genentech, Inc, Human Genome Sciences, Pfizer Inc, Roche, and UCB.
Because this course is meant to educate physicians with what is currently in use and what may be available in the future, there may be “off-label” use discussed in the presentations. Speakers have been requested to inform the audience when off-label use is being discussed.
It is the policy of The Office of Continuing Medical Education at The University of Texas Southwestern Medical Center to ensure balance, independence, objectivity, and scientific rigor in all directly sponsored and jointly sponsored educational activities.
Information and opinion offered by the speakers represent their viewpoints. Conclusions drawn by the audience should be derived from careful consideration of all available scientific information. Products may be discussed in treatment outside current approved labeling.
We gratefully acknowledge the financial support from AstraZeneca and Pfizer Inc.